Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.69 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.69 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | CCKBR | P32239 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750941 | 0.89 | KCNN4 (0.58) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL20772229 | 0.89 | KCNN4 (0.58) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL2361042 | 0.89 | KCNN4 (0.67) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL2403558 | 0.89 | KCNN4 (0.58) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL2391892 | 0.89 | KCNN4 (0.58) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL9182074 | 0.85 | KCNN4 (0.57) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL11199996 | 0.85 | KCNN4 (0.54) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL23995584 | 0.82 | KCNN4 (0.68) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL41130 | 0.82 | KCNN4 (1.00) | KCNN4KCNA3CYP11B1CYP11B2TSHR | |
| SCHEMBL2392101 | 0.82 | KCNN4 (0.72) | KCNN4KCNA3CYP11B1CYP11B2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994283-A | Beta-D-galactopyranose compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-11-22 | — | — | CN | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114206848-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-105050598-B | Novel compounds as ERK inhibitors | 默沙东公司 | 2018-04-27 | — | — | CN | disclosed |
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| EP-2770987-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| CN-103261196-A | Pyrazolopyridines as inhibitors of the kinase lrrk2 | MEDICAL RES COUNCIL TECHNOLOGY | 2013-08-21 | — | — | CN | disclosed |
| WO-2013063214-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026263-B2 | Methods for inhibiting neoproliferative changes in blood vessel walls | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-09-27 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070072811-A1 | Bifunctional heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | disclosed |
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | disclosed |
| WO-1997001551-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-16 | — | — | WO | disclosed |
| CN-1116425-A | New cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-02-07 | — | — | CN | disclosed |
| EP-0091130-B1 | CEPHALOSPORIN DERIVATIVES, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072811-A1 | Bifunctional heterocyclic compounds and methods of making and using the same | PCNA, DCX, HPGDS | KCNN4 3906/4885KCNA3 4679/4885CYP11B1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.